November 29, 2022
Loading...
You are here:  Home  >  'Neulasta'
Latest

Amgen releases 4th quarter earnings

By   /  Thursday, January 30th, 2020  /  Earnings, Health Care & Life Science, Latest news  /  Comments Off on Amgen releases 4th quarter earnings

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen earnings per share up 20 percent due to higher product sales

By   /  Thursday, July 26th, 2018  /  Earnings, East Ventura County, Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen earnings per share up 20 percent due to higher product sales

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

FDA approves biosimilar of Amgen’s Neulasta

By   /  Monday, June 4th, 2018  /  East Ventura County, Health Care & Life Science, Latest news, Technology  /  Comments Off on FDA approves biosimilar of Amgen’s Neulasta

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen beats analysts’ revenue, earnings per share estimates

By   /  Thursday, October 27th, 2016  /  Earnings, Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen beats analysts’ revenue, earnings per share estimates

Amgen revenues increased 2 percent during the third quarter as it beat analysts’ revenue and earnings per share estimates thanks to cost-cutting measures and lower research measures. Revenues for the Thousand Oaks-based biotech giant increased from $5.72 billion during the third quarter of 2015 to $5.81 billion in 2016, which beat analyst estimates of $5.73 Read More →

Latest

Silence is deafening when new drugs are not approved

By   /  Friday, August 5th, 2016  /  Columns, Latest news, Technology  /  Comments Off on Silence is deafening when new drugs are not approved

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen reports revenue increase in second quarter earnings

By   /  Wednesday, July 27th, 2016  /  Earnings, Health Care & Life Science, Latest news, Tri-County Public Companies, West Ventura County  /  Comments Off on Amgen reports revenue increase in second quarter earnings

Updated on July 27 at 4 p.m.: Amgen reported a 6 percent increase in revenue and a 15 percent increase in earnings per share in its second quarter earnings released July 27. Revenues grew to $5.7 billion due to higher sales of the company’s drugs Enbrel, Prolia, Kyprolis and Xgeva, and operating income increased 15 Read More →

Latest

FDA declines to approve Novartis biosimilar for Amgen’s Neulasta

By   /  Tuesday, July 19th, 2016  /  Health Care & Life Science, Latest news  /  Comments Off on FDA declines to approve Novartis biosimilar for Amgen’s Neulasta

The Food and Drug Administration has declined for now to approve a copycat version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based biotech giant Read More →